Current Report Filing (8-k)
2020年3月12日 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 11, 2020
Hepion Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36856
|
|
46-2783806
|
(State or other jurisdiction
|
|
(Commission
|
|
IRS Employer
|
of incorporation or organization)
|
|
File Number)
|
|
Identification No.)
|
399 Thornall Street, First Floor
Edison, NJ 08837
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (732) 902-4000
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock
|
|
HEPA
|
|
Nasdaq Capital Market
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨
|
Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Hepion
Pharmaceuticals, Inc. (the “Company”) intends to conduct meetings with third parties in which its corporate slide
presentation will be presented. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
The information
in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise
subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: March 11, 2020
|
HEPION PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Robert Foster
|
|
|
Robert Foster
|
|
|
Chief Executive Officer
|
Hepion Pharmaceuticals (PK) (USOTC:CTRVW)
過去 株価チャート
から 6 2024 まで 7 2024
Hepion Pharmaceuticals (PK) (USOTC:CTRVW)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Hepion Pharmaceuticals Inc (PK) (その他OTC): 0 recent articles
その他のHepion Pharmaceuticals, Inc.ニュース記事